Principal Investigator

Hua-Bing Li, Ph.D.

李华兵 研究员，国家杰青

Position：

Principal Investigator,

Shanghai Institute of Immunology

Assistant Professor Adjunct,

Department of Immunobiology,

Yale Medical School

上海交通大学医学院 上海市免疫学研究所

附属瑞金医院老年医学中心 特聘教授

Office： 86-021-63846590-776794

Email：huabing.li@shsmu.edu.cn

huabing.li@yale.edu

Office Location：Room 602, No.5 Bldg., West Area, 280 South Chongqing Rd., Shanghai.

上海市黄浦区重庆南路280号西5号楼602室

PROFILE @ SHSMU

Biography:

Dr. Li graduated from Nankai University with B.S. and M.S. degrees, then obtained his Ph.D. degree in Biochemistry in 2011 in Vincenzo Pirrotta lab at Rutgers, the state University of New Jersey, working on Polycomb mediated long-distance chromatin interactions in Drosophila. He continued his postdoc training with Dr. Richard Flavell at Yale University School of Medicine since 2012, working on regulatory RNAs and RNA epigenetic switches of the immune system.

Dr. Li established his independent lab at Shanghai Jiao Tong University School of Medicine since 2017. The lab is especially interested in the physiological functions and molecular mechanisms of RNA epigenetic modifications and related RNA binding proteins in immune cells and related immune disease with mouse disease models. Combined with the state-of-the-art technologies and international collaboration, we aim to reveal novel fucntions and mechanisms of inflammation and autoimmune disease, which will contribute to the identification of potential targets for anti-autoimmune and anti-tumor drug development.

 

Education & Experience：

Education

2005-2011, Rutgers University / UMDNJ, Piscataway, NJ, USA, Ph.D.

2002-2005, Nankai University, Tianjin, China, M.S.

1999-2002, Nankai University, Tianjin, China, B.S.  

Work Experience

2017-present, Shanghai Institute of Immunology, Principal Investigator  

2017-present, Yale University School of Medicine, Assistant Professor Adjunct

2012-2017, Yale University, Post-Doctoral Fellow

2011-2012, Rutgers University, Post-Doctoral Associate

Selected Publication

  1. Ding C#, Yu Z#, Sefik E#, Zhou J#, Kaffe E, Wang G, Li B, Flavell RA, Hu W, Ye Y, Li HB*. (2023). A Treg specific long non-coding RNA maintains immune-metabolic homeostasis in ageing liver. Nature Aging. 2023 Jul; READ

  2. Liu Y#, Zhou J#, Li X#, Zhang X#, Shi J#, Wang X, Li H, Miao S, Chen H, He X, Dong L, Lee GR, Zhen J, Liu RJ, Su B, Ye Y, Flavell RA*, Yi C*, Wu Y*, Li HB*. (2022) tRNA-m1A modification promotes T cell expansion via efficient MYC protein synthesis. Nature Immunology, 2022 Oct;23. READ

  3. Ding C#, Xu H#, Yu Z#, Roulis M, Qu R, Zhou J, Oh J, Craford J, Gao Y, Jackson R, Sefik E, Li S, Wei Z, Skadow M, Yin Z, Ouyang X, Wang L, Zou Q, Su B, Hu W*, Flavell RA*, Li HB*. (2022) RNA m6A demethylase ALKBH5 regulates the development of γδ T cells. Proc Natl Acad Sci U S A. 2022 Aug 16; READ

  4. Chen B#, Hu J#, Chen H, Bao R, Zhou Y, Zhan M*, Ye Y*, Li H*, Li HB*. (2022) DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nature Communications, 2022 April 19. READ

  5. Zhang T#, Ding C#*, Chen H# Zhao J, Chen J, Chen B, Mao K, Hao Y, Roulis M, Xu H, Kluger Y, Zou Q, Ye Y, Zhan M*, Flavell RA*, Li HB*. (2022) m6A mRNA modification maintains colonic epithelial cell homeostasis via NF-κb-mediated anti-apoptotic pathway. Science Advances, 2022 Mar 25;READ

  6. Zhou J#, Zhang X#, Hu J, Qu R, Yu Z, Xu H, Chen H, Yan L, Ding C, Zou Q, Ye Y, Wang Z, Flavell RA*, Li HB*. (2021) m6A Demethylase ALKBH5 Controls CD4+ T cell Pathogenicity and Promotes Autoimmunity. Science Advances, 2021 Jun 16;7(25):eabg0470. READ

  7. Tong J#, Wang X#, Liu Y#, Ren X, Wang A, Chen Z, Yao J, Mao K, Liu T, Meng FL, Pan W, Zou Q, Zhou Y, Xia Q*, Flavell RA*, Zhu S*, Li HB*. (2021) Pooled CRISPR Screening Identifies m6A as a Positive Regulator of Macrophage Activation. Science Advances, 2021 Apr 28; 7(18):eabd4742. READ

  8. Chen H#, Yao J#, Bao R, Dong Y, Zhang T, Du Y, Wang G, Ni D, Xun Z, Niu X, Ye Y*, Li HB*. (2021) Cross-talk of Four Types of RNA Modification Writers Defines Tumor Microenvironment and Pharmacogenomic Landscape in Colorectal Cancer. Molecular Cancer, 20(1):29. READ

  9. Gao Y*#, Vasic R#, Song Y#, Teng R, Gbyli R, Biancon G, Nelakanti R, Liu C, Kudo E, Lobben K, Liu W, Ardasheva A, Fu X, Wang X, Joshi P, Lee V, Dura B, Viero G, Iwasaki A, Fan R, Xiao A, Flavell RA*, Li HB*, Tebaldi T*, Halene S*. (2020) Activation of Double-Stranded RNA Innate Immune Response and Hematopoietic Failure upon Loss of METTL3-Mediated m6A RNA Modification. Immunity, 2020 Jun 16; READ

  10. Tong J#, Cao G#, Zhang T#, Sefik E, Vesely M, Broughton J, Zhu S, Li H, Li B, Chen L, Chang HY, Su B, Flavell RA*, Li HB*. (2018) m6A mRNA methylation sustains Treg suppressive functions. Cell Research, 28(2): 253-256. READ

  11. Li HB#*, Tong J#, Zhu S#, Batista PJ, Duffy EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y, Wang G, Broughton JP, Chen YG, Kluger Y, Simon MD, Chang HY, Yin Z*, Flavell RA*. (2017) m6A mRNA methylation controls T cell homeostasis by targeting IL-7/STAT5/SOCS pathway. Nature, 2017 Aug 17;548(7667):338-342. READ

  12. Hu B#, Jin C#, Li HB#, Tong J, Ouyang X, Cetinbas NM, Zhu S, Strowig T, Lam FC, Zhao C, Henao-Mejia J, Yilmaz O, Fitzgerald KA, Eisenbarth SC, Elinav E, Flavell RA. (2016) The DNA Sensing Aim2 Inflammasome Controls Radiation Induced Cell death and Tissue Injury. Science, 11 Nov 2016; READ